文献速递衰弱、肌少症与跌倒老年慢病共病管理

衰弱是美国退伍军人感染SARS-CoV-2后急性后遗症的风险因素:Delta与Omicron波次期间的研究

Frailty as a risk factor for post-acute sequelae of COVID-19 among US veterans during the Delta and Omicron waves.
PubMed 文献 · J Am Geriatr Soc · 2023-09-19

本研究为回顾性队列研究,纳入2021年7月至2022年2月间SARS-CoV-2检测阳性且感染后30天存活的245857名美国退伍军人,使用31项VA衰弱指数评估衰弱状态。结果显示,与健壮者相比,衰弱和衰弱前期与PASC风险分别增加41%和15%相关;感染前接种疫苗和加强针分别与PASC风险降低27%和33%相关。结论认为衰弱与PASC风险增加相关,疫苗接种与PASC风险降低相关,加强针进一步降低风险。

要点

  • 衰弱与PASC风险增加独立相关,衰弱者风险增加41%,衰弱前期增加15%。
  • 感染前接种疫苗与PASC风险降低27%相关,加强针进一步降低至33%。
  • 早期识别COVID-19患者的衰弱状态可能有助于PASC的早期发现和管理。

核心结论

  • 衰弱与感染SARS-CoV-2后发生PASC的风险增加相关。
  • 感染前接种疫苗与PASC风险降低相关,加强针进一步降低风险。
  • 早期识别COVID-19患者的衰弱可能有助于PASC的早期识别和管理。

研究设计与样本

  • 回顾性队列研究,使用VA COVID-19共享数据资源识别2021年7月至2022年2月间SARS-CoV-2检测阳性、既往无阳性检测且感染后30天存活的美国退伍军人。
  • 使用基于电子健康记录的31项VA衰弱指数计算衰弱状态,分为健壮(FI≤0.10)、衰弱前期(FI>0.10-<0.21)和衰弱(FI≥0.21)。
  • 采用Cox生存模型评估衰弱与PASC、疫苗接种与PASC的关联,并调整协变量。
  • 共纳入245857名COVID-19阳性退伍军人,平均年龄57.5±16.5岁,87.2%为男性,68.1%为白人,9.0%为西班牙裔。
  • 48.9%为健壮,28.3%为衰弱前期,22.7%为衰弱;40.6%完成全程疫苗接种,13.6%接种加强针。

主要发现

  • 中位随访143天(IQR=101)期间,23890名(9.7%)患者发生PASC。
  • 感染后6个月内,与健壮者相比,衰弱者PASC风险增加41%(aHR 1.40,95%CI 1.35-1.47),衰弱前期者增加15%(aHR 1.17,95%CI 1.11-1.19)。
  • 感染前接种疫苗与PASC风险降低27%相关(aHR 0.73,95%CI 0.71-0.75),加强针与降低33%相关(aHR 0.66,95%CI 0.63-0.69)。

关键数值与推荐

  • 衰弱分类标准:健壮FI≤0.10,衰弱前期FI>0.10-<0.21,衰弱FI≥0.21。
  • 衰弱者PASC风险aHR 1.40(95%CI 1.35-1.47),衰弱前期aHR 1.17(95%CI 1.11-1.19),参照组为健壮者。
  • 疫苗接种者PASC风险aHR 0.73(95%CI 0.71-0.75),加强针接种者aHR 0.66(95%CI 0.63-0.69)。

临床怎么用

  • 在COVID-19患者中早期评估衰弱状态,可能有助于识别PASC高风险人群并加强随访管理。
  • 鼓励符合条件的人群接种疫苗和加强针,以降低PASC风险。

局限性

  • 研究为回顾性队列设计,可能存在残余混杂。
  • 样本以男性白人退伍军人为主,外推至其他人群需谨慎。
  • 衰弱指数基于电子健康记录,可能存在测量偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Older populations have suffered the highest rates of SARS-CoV-2 infection and associated complications, including Post-Acute Sequelae of SARS-CoV-2 infection (PASC). Frailty is a geriatric syndrome that often coexists with COVID-19 infection. The vulnerability to stressors caused by multisystemic dysfunction that characterizes frailty may predispose older adults to develop PASC. METHODS: Retrospective cohort study using the VA COVID-19 Shared Data Resource to identify US veterans testing positive for SARS-CoV-2 between July 2021 and February 2022, without prior positive tests and who were alive 30 days after infection. Frailty was calculated using a 31-item VA Frailty Index generated from electronic health records. We categorized Veterans into robust (FI ≤ 0.10), prefrail (FI: >0.10- < 0.21), and frail (FI ≥ 0.21). We assessed the association between frailty and PASC and vaccination and PASC using Cox survival model, adjusting for covariates. RESULTS: We identified 245,857 COVID-19-positive veterans surviving 30 days after infection. The mean age was 57.5 ± 16.5 years; 87.2% were males, 68.1% were white, and 9.0% were Hispanic. Almost half of the sample (48.9%) were classified as robust, while 28.3% were pre-frail and 22.7% were frail; 99,886 (40.6%) were fully vaccinated, and 33,516 (13.6%) received booster doses. Over a median follow-up of 143 days (IQR = 101), 23,890 (9.7%) patients developed PASC. Within 6 months after infection, frailty and pre-frailty were associated with a 41% (adjusted HR [aHR]:1.40 (95% CI: 1.35-1.47) and 15% (aHR: 1.17 (95% CI: 1.11-1.19) increase in the risk of PASC compared with the robust, respectively. Vaccination and booster doses before infection were associated with a 27% (aHR: 0.73 (95% CI: 0.71-0.75) and 33% (aHR: 0.66 (95% CI: 0.63-0.69) reduction in the risk of developing PASC, respectively. CONCLUSIONS: Frailty was associated with an increased risk of developing PASC. Vaccination was associated with a decreased risk of PASC, further reduced by booster doses. Early recognition of frailty in patients with COVID-19 may assist in the early identification and management of PASC.

来源:J Am Geriatr Soc,查看原文。版权归原作者所有。

引用

  1. Hammel IS, Tosi DM, Tang F, et al. Frailty as a risk factor for post-acute sequelae of COVID-19 among US veterans during the Delta and Omicron waves. J Am Geriatr Soc. 2023. PMID: 37725480. doi:10.1111/jgs.18584

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。